Disclosure: EverLife Capital is a publication of general and regular circulation that provides impersonal, educational commentary for a general audience. Nothing here is personalized investment advice, an offer to sell, a solicitation to buy any security, or a recommendation that any reader take any specific action. This article discusses publicly announced corporate transactions and industry data for informational purposes only. No acquisition is guaranteed to occur, and no outcome, return, or future share-price performance is promised or implied. Positions: As of publication, I hold equity positions in Yuva Biosciences and Repair Biotechnologies. I do not hold positions in any other company discussed in this article. Compensation: I have not received compensation from any issuer, underwriter, dealer, or affiliate mentioned in this article. The SEC requires truthful, non-misleading, evidence-based claims and clear disclosure of material connections - this article is written in full compliance with those standards.
A few years back, I sold CuraDebt's servicing operations to a larger debt settlement operator. And going through that process - figuring out what they actually valued, what made them willing to write a check, and what would have killed the deal - taught me something that no business book quite captured: acquirers don't buy what's most impressive. They buy what solves their specific problem, right now, at a scale that matters to them.
I've been thinking about that experience a lot lately while building out EverLife Capital's universe of longevity biotech companies. We're tracking over 400 companies at various stages. And as I've watched acquisition after acquisition close in 2025 - Merck paying $10 billion for Verona, Sanofi paying $9 billion for Blueprint, Novartis paying $12 billion for Avidity - I keep seeing the same pattern play out. It's not the most elegant science that gets bought. It's the science that fits someone's specific strategic gap, is far enough along to de-risk the check, and is big enough to actually matter to a company doing tens of billions in revenue.
Start with the end in mind. That's a principle I've applied in business for decades. It applies here too. If you want to understand which biotech companies are most likely to attract serious acquisition interest - not as a prediction, but as a lens for understanding the industry - you have to start by understanding what acquirers are actually shopping for.
McKinsey analyzed the biopharma dealmaking landscape through 2025 and the data reinforces this: more than 70% of new molecular entity revenues since 2018 have come from externally sourced products. Big pharma's pipeline is built largely by buying what biotech invents. And yet they're getting more selective, not less. Deal volume peaked at roughly 4,900 annually in 2020 and fell to around 3,200 by 2023. Meanwhile aggregate deal value kept climbing, peaking at $191 billion in 2024.
Fewer deals, larger checks. A very deliberate buyer's market - with a very specific buyer's checklist.
70%+ Of NME revenues from external sources since 2018
$191B Peak biopharma deal value in 2024
↓35% Deal volume decline from 2020 to 2023
Here's what that checklist looks like in practice - illustrated with four deals that closed in 2025, totaling over $40 billion.
Filter 1 - Strategic Need Usually Comes Before Scientific Elegance
The first question a pharma business development team asks isn't "Is this the most elegant biology?" It's "What problem does this solve for us, right now?"
Large pharma constantly faces the patent cliff - the point where exclusivity on their biggest revenue drivers expires and generics or biosimilars flood in. That creates a perpetual urgency to source pipeline replacement. Pfizer, for example, has flagged approximately $1.5 billion in anticipated negative revenue impact from recent and expected generic and biosimilar competition embedded in their 2026 guidance. Merck's situation is even starker: Keytruda generated $29.5 billion in revenue in 2024 - 46% of the company's total - and its patent expires in 2028.
That's why Merck's $10 billion acquisition of Verona Pharma in July 2025 makes complete sense viewed through this lens. Merck described the transaction as aligning with its "science-led business development strategy" while expanding its cardio-pulmonary pipeline with Ohtuvayre (ensifentrine). Merck CEO Robert Davis said the deal delivers "near and long-term growth as well as value for shareholders." That's not just science talk. That's a strategic gap being filled.
Filter 2 - Buyers Pay The Most For Assets That Are Already De-Risked
Early-stage science can be extraordinary and still not attract large pharma interest at a reasonable valuation. That's because acquirers have to underwrite the probability of failure - and at Phase 1, that probability is very high. McKinsey's data shows a meaningful shift toward clinical-stage and approved-product acquisitions in 2022–2024, with preclinical dealmaking falling back to 2009 levels. Companies have become more selective around early-stage R&D, moving away from less established modalities and focusing on fewer, higher-conviction opportunities.
What this means for understanding pharma dealmaking: the closer an asset is to approval - or post-approval - the more a large acquirer can reliably underwrite the transaction. Approved products with commercial traction are essentially de-risked assets packaged into a company. That's a very different risk profile from a Phase 1 program, regardless of how compelling the underlying science may be.
Both of the largest deals from 2025 illustrate this exactly. Merck acquired Ohtuvayre after it had already received FDA approval in June 2024 and was showing rapid commercial uptake. Sanofi's $9.1 billion acquisition of Blueprint Medicines came when Ayvakit was generating $479 million in annual revenue with 60%+ year-over-year growth, and Blueprint was projecting $700–$720 million for the full year 2025 heading toward a $2 billion revenue target by 2030.
The asset still needs to clear regulatory risk for a big pharma buyer to get truly comfortable underwriting a multi-billion dollar deal. Late-stage programs, NDA-stage assets, and approved commercial products command significant premiums because they dramatically shorten the timeline to contribution and eliminate the binary risk of Phase 2/3 failure.
Filter 3 - Commercial Fit And Therapeutic Adjacency Matter As Much As The Science
An asset doesn't exist in isolation - it lands inside a commercial organization that either has the infrastructure to launch it or doesn't. Regulatory expertise, specialist relationships, existing prescriber networks, and medical affairs capabilities are all worth real money. Biotech companies with the right disease-area expertise are more valuable to an acquirer already operating in that space than they would be to someone building from scratch.
Sanofi's Blueprint acquisition is the cleanest example of this from 2025. Sanofi didn't just buy Ayvakit - they explicitly cited Blueprint's established presence among allergists, dermatologists, and immunologists as a key value driver that would enhance Sanofi's growing immunology pipeline. That's not a science argument. That's an argument about acquired commercial infrastructure. Blueprint brought a trained, specialized sales force and pre-existing prescriber relationships in exactly the physician community Sanofi was trying to build toward.
Filter 4 - Platform Stories Need Real Programs To Get Across The Finish Line
One of the most persistent myths in biotech investing is that a revolutionary platform - a novel delivery mechanism, a new modality, a breakthrough approach to targeting - is sufficient on its own to attract acquisition interest. It rarely is.
What large acquirers actually want is a platform story with late-stage programs attached. The platform provides future optionality. The programs justify the valuation today. McKinsey's data confirms this: the shift toward clinical-stage dealmaking reflects acquirers wanting to see real, near-term assets they can underwrite, not just a technology that might generate assets in five years.
Novartis's $12 billion acquisition of Avidity Biosciences (completed February 2026) is the best recent example. Novartis gained access to Avidity's muscle-directed Antibody Oligonucleotide Conjugate (AOC) platform - genuinely breakthrough RNA delivery technology. But the deal was structured around three specific late-stage programs: del-zota for Duchenne muscular dystrophy (with a BLA submission planned for 2026), del-desiran for myotonic dystrophy type 1, and del-brax for facioscapulohumeral muscular dystrophy.
Novartis said the acquisition "strengthens its late-stage neuroscience pipeline and advances its xRNA strategy" and is expected to support its 2025–2030 net sales CAGR target of 5–6%. The platform mattered. But without three late-stage clinical programs nearing commercialization, the deal almost certainly doesn't happen at $12 billion.
Filter 5 - The Asset Has To Be Large Enough To Move The Needle
A $500 million peak sales drug is interesting to a small biotech. To a company doing $60 billion in annual revenue, it barely registers. Big pharma acquirers need to see a credible path to blockbuster or near-blockbuster revenue contribution - generally defined as $1 billion or more in annual peak sales - for an acquisition to make internal sense against the cost of capital and integration complexity.
Every deal announcement from 2025 that I've looked at framed the target in terms of its expected growth contribution, not just its scientific novelty:
Merck on Verona/Ohtuvayre: "multibillion dollar commercial opportunity with potential to drive both near- and long-term revenue growth" and "expected to grow into the next decade"
Sanofi on Blueprint/Ayvakit: $479M in 2024 revenues, 60%+ YoY growth, Blueprint's own $2 billion by 2030 target
Novartis on Avidity: "expected to support 2025–2030 CAGR" and potential product launches before 2030 across three rare neuromuscular disease indications with limited treatment alternatives
This is worth noting in the context of longevity biotech specifically - not as a stock recommendation, but as an observation about where the sector currently sits relative to pharma's acquisition checklist. Most aging-related assets are still early enough that revenue models remain speculative, regulatory paths are still being established, and peak sales projections are difficult to substantiate. That may change as the science matures and commercial-stage longevity assets emerge. But for now, the scale filter is one reason longevity companies tend to attract strategic partnerships and licensing deals rather than full acquisitions at large premiums.
The Framework
Based on the McKinsey data and the four completed deals analyzed above, here's the consolidated filter set that appears to drive biotech acquisition decisions. This is a descriptive framework drawn from observed dealmaking patterns - not a prediction model, not investment advice, and not a suggestion that any company meeting these criteria will be acquired.
The Five Acquisition Filters
1 - Strategic need fit: Does this asset solve a specific pipeline gap, patent cliff exposure, or revenue replacement problem for a named buyer? If yes, which one?
2 - De-risking stage: Is the asset late-stage, NDA-pending, or already approved? The more clinical validation, the more a buyer can underwrite.
3 - Commercial and therapeutic adjacency: Does the buyer already have the specialist relationships, regulatory expertise, and launch infrastructure needed to commercialize this asset?
4 - Platform + programs: Is there a compelling platform story with concrete late-stage programs that justify the price today?
5 - Commercial scale: Is there a credible path to $1B+ in peak annual revenues that can move the needle for a large acquirer?
Notice what's not on that list: "most innovative science," "most novel mechanism," "most exciting biology." All of those can be true and still not produce an acquisition if the strategic need, de-risking, commercial fit, and revenue scale don't line up simultaneously.
What This Means for the Longevity Companies We Track - Now and in 5 to 10 Years
Here's where this gets personal for me. The whole point of EverLife Capital isn't just financial ROI - it's dual ROI. I want returns that also move the needle on my own healthspan. That means the companies I find most compelling are the ones working on the biology of aging itself: senolytics, mitochondrial function, epigenetic reprogramming, NAD+ metabolism, mTOR modulation, and related mechanisms.
But I'm also a realist. I've evaluated over 400 companies through our 25-Gate framework. The ones that clear the L-45 threshold are exceptional on the science. The harder question - the one this article is really about - is which of them are building toward something that pharma will eventually want to buy. And more importantly: are they building intentionally toward that, or just hoping the science speaks for itself?
Start with the end in mind. That's what the five filters above are really about. So let me apply them forward to longevity biotech specifically - not as a prediction, but as a thinking framework for what acquirers appear likely to care about as this sector matures.
Conflict of Interest Disclosure: I hold equity positions in Yuva Biosciences (a mitochondrial longevity company based in Birmingham, AL) and Repair Biotechnologies (a longevity biotech company). Both are discussed in general categorical terms below as examples within their respective areas. Nothing in this section is a recommendation to buy, sell, or hold securities in Yuva, Repair Biotechnologies, or any other company. Readers should weigh these conflicts accordingly.
What Pharma Is Likely Watching For in Longevity - Now and Over the Next Decade
Indication-anchored aging assets (now): Based on the dealmaking patterns described above, longevity companies that appear better positioned to fit pharma's existing acquisition checklist are those that have framed their lead program around a specific, approvable indication - not "aging" as a broad concept, but sarcopenia, metabolic dysfunction-associated steatohepatitis (MASH), age-related muscle loss, frailty, or Alzheimer's disease. A company with a senolytic approaching Phase 2 for a named indication has a more legible path to pharma BD conversations than one whose entire pitch is "we slow aging." FDA-approvable endpoints are what convert interesting biology into assets a pharma BD team can underwrite. This is an observation about dealmaking logic, not a prediction about any company's acquisition prospects.
Validated aging biomarkers as regulatory endpoints (3 to 5 years): One structural development that could change pharma's calculus on longevity M&A is FDA qualification of biological aging biomarkers - epigenetic clocks, proteomics-based aging scores, or composite functional measures - as surrogate endpoints for drug approval. If and when an agreed regulatory path exists to demonstrate that a drug measurably affects biological aging in a trial setting, longevity assets become more underwritable by pharma acquirers in the same way any late-stage clinical asset is underwritable today. Companies building their clinical programs around these emerging endpoints now are closer to the pipeline maturity curve that pharma dealmaking tends to favor - though no regulatory outcome is guaranteed.
GLP-1 adjacency and metabolic longevity (now, accelerating): The GLP-1 revolution has made metabolic health one of the most active commercial territories in pharma. Companies working on muscle preservation, metabolic aging, mitochondrial biogenesis, or fat-to-muscle ratio in the context of obesity treatment sit at an intersection that pharma BD teams with GLP-1 commercial infrastructure are already monitoring closely. The therapeutic adjacency filter applies here in a fairly straightforward way - large pharma organizations with established GLP-1 pipelines have documented strategic interest in assets that address downstream muscle loss and metabolic dysfunction, which GLP-1 drugs can leave unaddressed. This is an observation about strategic fit logic, not a claim about which companies in this space will or won't be acquired.
Mitochondrial and cellular energy platforms (3 to 7 years): Mitochondrial dysfunction intersects with aging, neurodegeneration, cardiovascular disease, and metabolic syndrome - which means a credible mitochondrial platform with late-stage programs could, in theory, address the strategic need of multiple potential acquirers. Applying the platform + programs filter: a mitochondrial company with programs approaching Phase 2/3 with clear commercial endpoints would fit pharma's observed preference for de-risked assets better than a platform-only story. Whether any specific company in this space meets that standard is a question each reader should evaluate independently. See the conflict disclosure above regarding my positions in Yuva Biosciences and Repair Biotechnologies.
Epigenetic reprogramming (5 to 10 years): Partial reprogramming approaches - technologies that appear capable of resetting cellular age markers rather than just slowing their progression - represent the most ambitious frontier in longevity science. The commercial path is still being defined. Companies including Altos Labs and Retro Biosciences are among those working toward early human proof-of-concept data. If and when credible human data emerges, the strategic rationale for large pharma to acquire or partner with reprogramming platform companies would likely strengthen - consistent with the same dealmaking logic described throughout this article. That outcome is speculative and may be many years away or may not occur at all. This is background context on where the science is heading, not a forward-looking statement about any company's value or acquisition prospects.
The through-line across all five of these is the same observation from the CuraDebt sale: the buyer's needs have to be legible. When I sold to a debt settlement operator, they weren't buying my history or my brand for its own sake - they were buying a specific, predictable, performing asset of clients. Longevity companies that build their development strategy with acquirer logic in mind - choosing indications, endpoints, and commercial narratives that map to observed pharma dealmaking priorities - are building toward something more structurally legible to potential acquirers than those that assume the science will eventually speak for itself. That's an observation about business development strategy, not a prediction about any company's future or a recommendation to invest in any company in this space.
It hasn't always worked that way. But looking at over $40 billion in deals from 2025, I think the pattern is clear enough to take seriously.
Bottom Line
Big pharma doesn't acquire what's most interesting - it acquires what's most useful, most de-risked, and most commercially scalable. When I sold part of CuraDebt, the acquirer wasn't moved by my track record alone - they were moved by a predictable asset of clients. Longevity biotech M&A appears to follow the same logic. The dual ROI thesis behind EverLife Capital - financial returns alongside science that advances human healthspan - depends on the sector eventually producing companies that clear pharma's checklist. Understanding what that checklist looks like today, and where it appears to be heading, is the context this article is meant to provide. None of it is investment advice, and none of it predicts that any specific company will be acquired.
Nothing in this article is a recommendation to buy, sell, or hold any security. No company discussed here is identified as a likely acquisition target, and no reader should act on the information in this article as if it were personalized investment advice. Past deal patterns do not guarantee future M&A activity. This publication qualifies as a bona fide publication of general and regular circulation under the Investment Advisers Act of 1940 - it provides only impersonal, disinterested educational commentary and does not tailor advice to individual readers. Always consult a licensed financial professional before making investment decisions.
Sources & Further ReadingMcKinsey - Pulse Check: Key Trends Shaping Biopharma Dealmaking in 2025
Merck - Acquisition Announcement: Verona Pharma (July 9, 2025)
Merck - Acquisition Completion: Verona Pharma (October 7, 2025)
Sanofi - Acquisition Announcement: Blueprint Medicines (June 2, 2025)
Sanofi - Acquisition Completion: Blueprint Medicines (July 18, 2025)
Novartis - Acquisition Announcement: Avidity Biosciences (October 26, 2025)
Novartis - Acquisition Completion: Avidity Biosciences (February 27, 2026)
Bristol Myers Squibb - Acquisition: Karuna Therapeutics (December 2023)